ArticleThe Journal of rheumatology2013
Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
Article in The Journal of rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis.Arthritis care & research · 2019Guideline
- Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatric rheumatology online journal · 2016Trial
- Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First-Line Therapy.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- The effect of anti-TNF α therapy on refractory non-infectious pediatric uveitis in Saudi Arabia.BMC ophthalmology · 2026Article
- Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic.Arthritis care & research · 2025Article
- The management of adult and paediatric uveitis for rheumatologists.Nature reviews. Rheumatology · 2024Review
- Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry.Ophthalmology and therapy · 2023Article
- Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.Ophthalmology and therapy · 2023Article
- Risk Factors Leading to Anti-TNF Alpha Therapies in Pediatric Severe Uveitis.Frontiers in pediatrics · 2022Article
- Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics.Frontiers in pediatrics · 2022Article
- Diagnosis and treatment of uveitis associated with juvenile idiopathic arthritis.Medicine and pharmacy reports · 2021Article
- Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.Annals of eye science · 2021Article
- Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.Rheumatology (Oxford, England) · 2019Article
- Update on the management of uveitis in children: an overview for the clinician.Expert review of ophthalmology · 2019Article
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.Annals of the rheumatic diseases · 2018Article
- Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis.Ocular immunology and inflammation · 2018Article
- Adalimumab for the treatment of refractory noninfectious paediatric uveitis.International ophthalmology · 2017Article
- Outcome of Juvenile Idiopathic Arthritis Associated Uveitis in Two Disease Subtypes.Archives of rheumatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 2 countries.
Funding
Abstract
objectiveTo evaluate the outcome of tumor necrosis factor-α inhibition (anti-TNF) for pediatric uveitis.
methodsWe retrospectively assessed children (age ≤ 18 yrs) with noninfectious uveitis receiving anti-TNF at 5 uveitis centers and 1 pediatric rheumatology center. Incident treatment success was defined as minimal or no uveitis activity at ≥ 2 consecutive ophthalmological examinations ≥ 28 days apart while taking no oral and ≤ 2 eyedrops/day of corticosteroids. Eligible children had active uveitis and/or were taking higher corticosteroid doses.
resultsAmong 56 eligible children followed over 33.73 person-years, 52% had juvenile idiopathic arthritis (JIA) and 75% had anterior uveitis (AU). The Kaplan-Meier estimated proportion achieving treatment success within 12 months was 75% (95% CI 62%-87%). Complete absence of inflammatory signs with discontinuation of all corticosteroids was observed in an estimated 64% by 12 months (95% CI 51%-76%). Diagnoses of JIA or AU were associated with greater likelihood of success, as was the oligoarticular subtype among JIA cases. In a multivariable model, compared to those with JIA-associated AU, those with neither or with JIA or AU alone had a 75%-80% lower rate of achieving quiescence under anti-TNF, independent of the number of immunomodulators previously or concomitantly prescribed. Uveitis reactivated within 12 months of achieving quiescence in 14% of those continuing anti-TNF (95% CI 6%-31%). The incidence of discontinuation for adverse effects was 8%/year (95% CI 1%-43%).
conclusionTreatment with anti-TNF was successful and sustained in a majority of children with noninfectious uveitis, and treatment-limiting toxicity was infrequent. JIA-associated AU may be especially responsive to anti-TNF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.